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Hyogo, JapanA B S T R A C TObjectives: In Japan, cost-effectiveness evaluation was implemented
on a trial basis from ﬁscal year 2016. The results will be applied to the
future repricing of drugs and medical devices. On the basis of a
request from the Central Social Insurance Medical Council (Chuikyo),
our research team drafted the ofﬁcial methodological guideline for
trial implementation. Here, we report the process of developing and
the contents of the ofﬁcial guideline for cost-effectiveness evaluation.
Methods: The guideline reﬂects discussions at the Chuikyo sub-
committee (e.g., the role of quality-adjusted life-year) and incorpo-
rates our academic perspective. Team members generated research
questions for each section of the guideline and discussions on these
questions were carried out. A draft guideline was prepared and
submitted to the Ministry of Health, Labour and Welfare (MHLW),
and then to the subcommittee. The draft guideline was revised on
the basis of the discussions at the subcommitte, if appropriate.
Results: Although the “public health care payer’s perspective” is
standard in this guideline, other perspectives can be applied asee front matter Copyright & 2016, International S
r Inc. This is an open access article under the CC
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ama 351-0197, Japan.necessary depending on the objective of analysis. On the basis of
the discussions at the subcommittee, quality-adjusted life-year
will be used as the basic outcome. A discount rate of 2% per annum
for costs and outcomes is recommended. The ﬁnal guideline
was ofﬁcially approved by the Chuikyo general assembly in
February 2016. Conclusions: This is the ﬁrst ofﬁcially approved
guideline for the economic evaluation of drugs and medical devices
in Japan. The guideline is expected to improve the quality and
comparability of submitted cost-effectiveness data for decision
making.
Keywords: cost-effectiveness analysis, discount, guideline, productivity
loss, QALY.
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Economic evaluation previously was largely unused in decision
making as applied to the reimbursement or pricing of health care
technologies (e.g., drugs, medical devices, and interventions) in
Japan. Ever since 1992, when new medicines are added to the
reimbursement list for public health care insurance, economic
evaluation data can be submitted to the Ministry of Health,
Labour and Welfare (MHLW; Ministry of Health and Welfare at
the time). However, in Japan, almost all approved drugs are
automatically reimbursed without referring to cost-effectiveness
data. In addition, there is a lack of clear rules regarding how to
use the submitted data for pricing. Therefore, even if economic
data are submitted, many pharmaceutical companies do not
believe that such data are reﬂected in the decision making on
their products. As a result, economic data for only 8 new drugs
were submitted to the MHLW from ﬁscal year (FY) 2006 to 2011,although reimbursement for 256 drugs was provided during the
same period. With respect to medical devices and interventions
(e.g., diagnosis and surgery), the MHLW requests economic data
for reimbursement, but for the most part, these analyses merely
compare costs (cost analysis) or are used for cost minimization
(Table 1) [1].
In Japan, the ofﬁcial price of drugs and medical devices is
determined by two methods: the cost calculation method and the
similar efﬁcacy comparison method. If a new product is rated as
innovative, a premium can be applied to the daily price of a
comparator (similar efﬁcacy comparison method) or proﬁt rate of
a product (cost calculation method). The ofﬁcial price is revised
every 2 years on the basis of results of the market price survey.
Such prices and pricing systems for medicines, and devices are
determined (strictly speaking, advised to the minister of MHLW)
by a council established by the MHLW called the Central Social
Insurance Medical Council (Chuikyo). From FY2012, discussions onociety for Pharmacoeconomics and Outcomes Research (ISPOR).
BY-NC-ND license
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Table 1 – Present state of economic evaluation submitted to the MHLW [1].
Analysis Medicines* Medical devices† Interventions‡
CEA with QALY 3 1 0
CEA with other outcomes 4 1 0
Cost-beneﬁt analysis 0 1 0
Others (e.g., cost analysis, cost minimization) 1 20 125
Total 8 23 125
CEA, cost-effectiveness analysis; FY, ﬁscal year; MHLW, Ministry of Health, Labour and Welfare; QALY, quality-adjusted life-year.
* Data only for 8 new drugs, reimbursed from FY2006 to FY2011.
† There were 23 new devices with new functions, reimbursed in FY2011.
‡ There were 125 interventions for which requests were sent for inclusion in the reimbursement list by academic societies in FY2011.
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that is, the Special Committee on Cost-Effectiveness Evaluation,
which consists of 16 individuals (6 representatives of health care
payers, 6 health care professionals, and 4 public interest [e.g.,
academics]), in addition to 4 industries and 3 health economists
(coauthors: T. Fukuda, S. Ikeda, and T. Takura) as nonvoting
members. Japan is one of the fastest aging countries in the world,
and consequently suffers from a rapid rise of health care
expenditures. This situation is exacerbated by newly developed
and high-priced health care technologies such as anticancer and
antihepatitis drugs. Despite this, cost-effectiveness has not been
extensively used for health care policy decision making. Over the
course of 4 years of discussions, the Chuikyo subcommittee
members reached a consensus that cost-effectiveness evaluation
(MHLW refers to economic evaluation as such) should be imple-
mented on a trial basis from FY2016. The results will be applied to
the future repricing of drugs and medical devices. According to
their discussions, demonstrating the validity of ofﬁcial prices
determined by the government from the perspective of cost-
effectiveness is important. They also requested the consideration
of a full-scale implementation and to expand the target technol-
ogy to interventions using expensive devices by FY2018, that is,
the year in which the pricing system is scheduled to be revised
next. These activities are supported by the Basic Policy on
Economic and Fiscal Management and Reform 2015 [2] as part
of the Japanese government's policy.
In the trial implementation of cost-effectiveness evaluation,
manufacturers are requested to submit economic data to the
MHLW. This evaluation, however, does not target all drugs and
devices. Target products are determined by the Chuikyo, and
selection criteria have already been set. First, regarding listed
technologies for which reimbursement decisions were made
between FY2012 and FY2015, four categories were set as target
criteria for the recalculation of prices: 1) the highest premium
rate, 2) 10% or more premium and the highest sales, in both of
two pricing methods (the cost calculation method and the similar
efﬁcacy comparison method), excluding rare intractable diseases.
The results of this evaluation are to be reﬂected in ofﬁcial prices
with the next revision (in FY2018). Nevertheless, how to reﬂect
the results has not yet been determined. This issue will be
discussed by the Chuikyo and a consensus will be reached by
the end of FY2017. Second, evaluations will be submitted for
newly reimbursed technologies from FY2016 with the expectation
of large sales to serve as reference material, and will not be
reﬂected in ofﬁcial prices.
To apply the results of economic evaluation to health care
decision making, there is a need to standardize the methods of
cost-effectiveness evaluation. In the absence of guidelines, the
methodology and quality of economic evaluation may vary
widely. This leads to low comparability across different analyses,
as well as low-quality analyses. An ofﬁcial guideline for economicevaluation has yet to be established in Japan, although our
research team previously developed a guideline for academic
researchers [3]. Many regions in Asia, such as Korea [4,5], Taiwan
[6], and Thailand [7], as well as European countries have ofﬁcial
guidelines. For this reason, our research team was asked to
develop a methodological guideline for cost-effectiveness evalu-
ation by the Chuikyo for trial implementation. Our submitted
draft guideline was approved by the Chuikyo, and as a rule
manufacturers must carry out the analysis stipulated by the
guideline. When difﬁculties arise with following the guideline,
manufacturers are asked to have a preliminary consultation with
authorities to discuss the analysis method. Here, we report the
process of developing and the contents of the ofﬁcial guideline
for cost-effectiveness evaluation.Process and Methods
Main methodological issues were continually discussed at meet-
ings of the Special Committee on Cost-Effectiveness Evaluation of
the Chuikyo (hereafter, “subcommittee”) from FY2012. Most of
the subcommittee members were not experts in economic
evaluation, and some members had competing interests with
each other. Three coauthors explained the concept of economic
evaluation and technical terms, answered questions, and pro-
vided comments from the perspective of experts. These discus-
sions led to the ofﬁcial publication of two interim reports from
the subcommittee in September 2013 and August 2015. By August
2015, members of the subcommittee had reached a consensus on
the following four points: 1) choice of outcomes, 2) range of costs,
3) comparators, and 4) data sources. The choice of outcomes was
one of the most controversial issues within the subcommittee.
On one hand, some members such as from medical associations
and the industry strongly opposed the mandatory use of quality-
adjusted life-year (QALY), as required by the National Institute for
Health and Care Excellence (NICE) in England/Wales. On the other
hand, some members, including insurers and health economists,
supported the use of QALY. After long deliberations, a consensus
was reached on the function of QALY, that is, QALY should be
used as a basic outcome, but other outcomes are allowed to be
used depending on the characteristics of the technology.
The second point was addressed as follows: Productivity loss
should not be included in the costs in base-case analysis.
According to subcommittee discussions, the estimation of pro-
ductivity loss is less reliable because such loss largely varies
depending on the estimation method. In addition, if productivity
loss is much greater than the health care costs, the productivity
loss would account for the major part of the cost. This makes it
difﬁcult to evaluate public health care expenses. The consensus
regarding the third point was that the health care technology that
is replaced by a new one and is used widely in clinical practice
Table 2 – Summary of Japanese guideline for cost-
effectiveness evaluation.
Reference case
Perspective “Public health care payer’s perspective” is
considered standard. Other
perspectives can be applied, as
necessary.
Target population Patients who meet the indication of the
technology at the time of analysis
Comparator Technology, reimbursed by public health
insurance, widely used in clinical
practice and expected to be to a large
extent
Additional beneﬁt The additional beneﬁt in terms of
effectiveness, safety, and/or other
factors of the technology should be
evaluated on the basis of a systematic
review.
Method of analysis CEA (basically, CUA should be used)
Results of analysis Incremental cost-effectiveness ratio
Subgroup analysis Should be performed if needed
Time horizon Long enough to evaluate the value of
health care technologies
Outcome measure QALY should be used as a basic outcome.
Methods to derive
QOL score
Preference-based instruments with
scoring algorithms developed in Japan
Mapping Yes
Sources of clinical
data
Systematic review
Indirect
comparison
Yes
Costs to be
included
All costs paid by public insurers, central
and local governments, and patients;
productivity loss, depending on choice
of perspective
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point, data used in the evaluation should be based on a system-
atic review, the importance of which was emphasized in sub-
committee discussions.
In the interim report published in August 2015, the subcom-
mittee also agreed that the guideline for cost-effectiveness
evaluation would be drafted by our research team, with funding
from the MHLW. This guideline must reﬂect the aforementioned
key discussions of the subcommittee, although many of the
technical details had not been worked out yet. Our research team
considered the remaining issues from an academic perspective.
Our suggested guideline [3] for academic researchers was
already presented to the subcommittee as reference material in
December 2013. Therefore, we revised that guideline to reﬂect the
contents of the subcommittee discussions and considered the
requirements for trial implementation (e.g., to evaluate both new
and already-listed technologies). Team members generated
research questions for each section of the guideline. Some
questions were related to methodological issues. Discussions on
these questions were carried out by referring to various docu-
ments (such as the guidelines of other countries), technical
documents generated by health technology assessment (HTA)
agencies, published articles, and original systematic reviews, as
appropriate. Guidelines from other countries were available from
the respective HTA agency Web sites. Our team members
searched PubMed and a Japanese medical database (Ichushi) for
published articles. After internal discussions, a draft guideline
was prepared and submitted to the MHLW, and then to the
subcommittee. The draft guideline was also reviewed by manu-
facturers of drugs and medical devices, and their comments were
reﬂected in the draft guideline, when appropriate. An updated
version of the guideline was submitted to the subcommittee in
November 2015, and a version with further minor revisions was
submitted in January 2016. In February 2016, our guideline was
ofﬁcially approved by the Chuikyo general assembly. Although
the original version of the guideline is in Japanese, we translated
it into English.Sources of costs Medical fee schedule and drug price list
set by the MHLW
Estimation of
productivity loss
Human capital method
Discount rate 2% (sensitivity analysis 0–4%)
Modeling Yes
Sensitivity
analysis
Deterministic and probabilistic sensitivity
analyses
Reporting The style set should be used. The analysis/
review results should be made public.
CEA, cost-effectiveness analysis; CUA, cost-utility analysis; MHLW,
Ministry of Health, Labour and Welfare; QALY, quality-adjusted
life-year; QOL, quality of life.Results
Referring to the guidelines of other countries [5–22] and previ-
ously proposed guidelines for academic researchers in Japan
[3,23], we decided to include the following 15 sections in the
guideline: 1) objectives, 2) perspective of analysis, 3) target
population, 4) comparator(s), 5) additional beneﬁt in effective-
ness/safety, 6) method of analysis, 7) time horizon, 8) choice of
outcome, 9) sources of clinical data, 10) calculation of costs, 11)
long-term care costs and productivity loss, 12) discounting, 13)
modeling, 14) uncertainty, and 15) reporting/publication. The full
text of the developed guideline is provided as an Appendix. A
summary of the guideline is presented in Table 2.
Perspective of Analysis
The range of costs for economic evaluation is determined by the
perspective of analysis. Analysis from the “public health care
payer’s perspective” should include only public medical costs,
which are generally covered by public health care insurance in
Japan. In this guideline, the “public health care payer’s perspec-
tive” is a perspective for base-case analysis on the basis of the
subcommittee discussions and must be included even when
other perspectives are applied. In Japan, costs of health care
technologies for prophylaxis (e.g., vaccinations) are not included
in public medical costs. Nevertheless, if these costs are paid for
using public funding, they can be included in costs in addition to
an analysis from the “public health care payer’s perspective.”Costs of long-term care for the elderly in Japan are reimbursed
by public long-term care insurance. When considering this social
security system, the “public health care and long-term care
payer’s perspective” can be used to add the costs of public
long-term care to public medical costs.
If the introduction of a health care technology directly
inﬂuences the productivity of patients, it is acceptable to perform
an analysis that considers broader costs and counts productivity
loss as a cost. Analyses that include productivity loss are some-
times referred to as being from a “societal perspective.” This
term, however, is somewhat misleading in that a strict societal
perspective must reﬂect all resource consumption in society,
measured by opportunity costs. Therefore, in this guideline, we
avoided the use of “society” in the names of perspectives on the
basis of a report from the ISPOR taskforce [24,25]. This is in line
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ommends the “limited societal perspective.”
The names of perspectives are not globally consistent. The
French guideline [16] recommends use of the “collective perspec-
tive,” which considers only direct medical costs. The Belgian
guideline [17] uses the term “perspective of health care payer,”
and the guideline in New Zealand uses “perspective of funder”
[19]. Although the names of these perspectives differ, our per-
spective of base-case analysis is identical with these guidelines. It
is noteworthy that the Canadian guideline [10] applies the
perspective of the publicly funded health care system and
recommends the inclusion of time costs to patients and their
families, which differs from the Japanese guideline.
The guidelines of England/Wales [20], Scotland [11], and Ire-
land [14] state that social care costs should be included in the
base-case analysis. Other countries (e.g., the Netherlands [22],
Sweden [9], Norway [18], Finland [21], Portugal [8], and Taiwan [6])
apply the “societal perspective.” Inclusion of these “additional”
perspectives is permitted in the Japanese guideline, although the
“public health care payer perspective” is a perspective for the
base-case analysis.
Target Population and Comparators
Patients who meet the indication of the technology should be
considered as the target population. As with other guidelines, the
replaced and widely used technology in clinical practice should
be used as a comparator(s). Considering the evaluation of
already-listed technologies, the comparator is limited to technol-
ogies that exist when the new technology is introduced. If
multiple technologies are potential candidates to be a compara-
tor, the technology should be selected on the basis of the extent
of replacement, similarities in technology when determining the
ofﬁcial price, cost-effectiveness, and other factors.
If different major populations and/or comparators can be
selected, and cost-effectiveness varies depending on them, an
analysis should be conducted for each population and compara-
tor. Nevertheless, as multiple analyses are often difﬁcult, such
situations should be discussed at preliminary consultations.
Additional Beneﬁt in Effectiveness/Safety
Before cost-effectiveness is calculated, the additional beneﬁt of
the technology in terms of effectiveness/safety must be evaluated
on the basis of a systematic review. The guideline recommends
that a PICO-style (P: patient; I: intervention; C: comparator; O:
outcome) research question be provided. If a head-to-head
comparison does not exist, an indirect comparison is allowed. If
there is no clear additional beneﬁt (i.e., if incremental effective-
ness is 0), a cost comparison with the comparator must be
performed.
Method of Analysis
In general, economic evaluation is classiﬁed into four types of
analyses [26]: 1) cost minimization analysis (CMA; costs are
calculated only when an equivalence of outcome is shown), 2)
cost-effectiveness analysis (CEA; outcomes are measured by a
natural unit such as life-years gained or event avoided), 3) cost-
utility analysis (CUA; QALY is used as the outcome unit), and 4)
cost-beneﬁt analysis (CBA; outcomes are valued in monetary
units). CMA is treated as a part of CEA by Drummond et al. [27].
CMA, CEA, and CUA are occasionally regarded as the same
type of analyses because outcomes and costs are calculated
separately with different units. In this guideline, they are treated
as the same CEA, and CEA is recommended in this sense. This
usage of CEA conforms to subcommittee discussions. In addition,incremental cost-effectiveness ratio should be used for the
results of CEA without a dominant or dominated case.
Choice of Outcome Measure
QALY should be used as a basic outcome in this guideline on the
basis of the subcommittee discussions. Other outcomes can be
used depending on the characteristics of the disease, drugs, and/
or medical devices. If QALY is not selected as an outcome,
appropriateness must be discussed through a preliminary con-
sultation that considers the characteristics of the drugs, medical
devices, or other factors.
QALY is the most preferred outcome measure in the guide-
lines of many countries (e.g., England/Wales [20], Scotland [11],
the Netherlands [22], Sweden [9], Finland [21], Norway [18],
Ireland [14], and New Zealand [19]), and is one of the preferred
outcome measures in other countries (e.g., France [16], Belgium
[17], Canada [10], Australia [12], and Poland [13]). It is noteworthy
that French and Belgian guidelines recommend the use of only
life-year (LY) or QALY. The Japanese guideline prefers QALY and
is in line with the former countries in this regard, but it also
recommends that an LY-based analysis be submitted if the
evaluated technology impacts LYs.
When new quality-of-life (QOL) data for economic evaluation
are collected, preference-based measures with scoring algorithms
developed in Japan should be used. For example, the EuroQol
ﬁve-dimensional questionnaire (EQ-5D [28-30]) meets this
requirement. Direct methods such as standard gamble and time
trade-off are less preferred. Nevertheless, in this guideline,
because only a few domestic surveys on QOL scores are available,
this rule cannot be applied to all existing QOL scores used for
economic evaluation. If QOL data are not available, QOL scores
converted from other patient-reported outcome data by mapping
are also allowed.
In the guidelines of England/Wales [20], the Netherlands [22],
and New Zealand [19], only the use of the EQ-5D is recom-
mended. The French guideline [16] allows the use of the Health
Utilities Index 3 in addition to the EQ-5D. The guidelines of some
countries (e.g., Belgium [17], Norway [18], and Ireland [14]) do not
refer to any speciﬁc instrument, although they recommend the
use of generic preference-based measures rather than direct
methods. The guidelines of the other countries do not have a
preference between direct and indirect methods.
Costs
Costs are calculated from the sum of each item’s subtotal costs,
which can be obtained by multiplying unit costs by medical
resource consumption. The latest (not at the time of consump-
tion) medical fee schedules and drug price list set by the MHLW
should be referred to for unit costs. In some cases such as claims
data analysis (of public health care insurance in Japan), it may be
difﬁcult to adjust unit costs by the latest fees or prices. If
sensitivity analysis conﬁrms that the results of CEA are not
inﬂuenced by differences in unit costs, costs can be calculated
without adjustment.
In Japan, some hospital costs are reimbursed by a fee-for-
service system and others by a diagnosis procedure combination/
per-diem payment system, similar to the diagnosis-related
group/prospective payment system in terms of inclusive pay-
ment. The fee-for-service system is recommended for calculation
of hospital costs. When costs such as adverse events and future
events are difﬁcult to calculate on a fee-for-service basis, average
prospective payment may be applied, but not for the target
technology.
There is some controversy regarding how to treat unrelated
medical costs in economic evaluation [31–37]. Treatment of high
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stroke and leads to prolonged life and increased unrelated
medical costs (e.g., dementia, diabetes, and dialysis). The present
guideline recommends the exclusion of unrelated medical costs
given the difﬁculty of rigid estimations. The guidelines of many
countries also recommend not including unrelated medical costs.
Interestingly, however, the Swedish guideline [9] states that all
unrelated costs (including all costs relating to social security etc.)
should be included as “consumption minus production.”
Productivity Loss
Productivity loss, caused by missing work or being less productive
because of disease, can be included in costs depending on the
selected perspective. When included in the analysis, analysis with-
out productivity loss should also be conducted simultaneously.
The range of productivity loss included in the analysis can
include family members or friends rather than patients alone.
According to this guideline, only a productivity loss directly
attributable to the health care technology (e.g., shortened hospi-
tal stay) is permitted for inclusion. An indirect productivity loss
resulting from an improvement in the patient’s health status (e.
g., survival period extension) should not be included in produc-
tivity loss to avoid double counting (i.e., counting a factor for both
effectiveness and costs) and overestimation.
Productivity loss estimation based on lost wages is referred to
as the “human capital method.” If full employment is not
achieved, however, the work is often performed by other people
and long-term productivity may not be lost. There is some
insistence that only friction costs [38,39] should be included on
the basis of the period needed to restore the initial production
level. Indeed, economic evaluation guidelines of some countries
(e.g., the Netherlands) recommend the friction costs method [40].
In the Belgian guideline [17], friction costs are used for long-term
absence on the basis of the notion that “vacant workplaces can be
ﬁlled again within a certain period of time,” although the human
capital method should be used for short-term absence. In the
Japanese guideline, the human capital method is recommended
for ease of calculation; nevertheless, productivity loss arising
from outcome improvements (i.e., one of long-term productivity
losses) cannot be included.
The human capital method is also recommended in many
countries (e.g., France [16], Belgium [in case of short-term
absence] [17], and Poland [13]). Some economic evaluations
include time costs for hospital visits or hospitalization (e.g.,
Canadian guideline [10]), even if they are unrelated to a reduction
in work. For a more conservative estimation, however, time costs
should not be included in this guideline.
Discounting
A discount rate of 2% per annum for costs and outcomes is
recommended. We further recommend that the discount rate be
changed from 0% to 4% per annum for sensitivity analysis.
A discount rate of 3% per annum is often used, for example, as
suggested by a Washington panel [41], but there is no clear
rationale for using this rate in Japan. Recommended discount rates
vary by country. For example, a discount rate of 3% is used in
Sweden [9] and Finland [21]; 3.5% in England/Wales [20], Scotland
[11], Ireland [14], and New Zealand [19]; 4% in France [16] and
Norway [18]; and 5% in Canada [10], Australia [12], Portugal [8],
South Korea [5], and Taiwan [6]. There are different methods and
views regarding the determination of discount rates [42–47]. One is
based on the real interest rate of low-risk bonds (e.g., long-term
government bonds) [47]. The nominal interest rate of 10-year
Japanese government bonds over the past decade ranged from
0% to 1.5%, deﬂation has continued, and the consumer price indexhas increased by an average of 1% to 1% per annum. Considering
these factors, a discount rate of 3% per annum may be too high.
The present guideline thus uses a discount rate of 2% per annum.
This rate, however, should be reconsidered if economic conditions
in Japan change substantially.
In some countries, different discount rates for costs and
outcomes are applied with the assumption that the value of
health will increase [42]. For example, discount rates in the
Netherlands [22] and Belgium [17] are 4% and 3%, respectively,
for costs, and 1.5% for outcomes in both countries. In Poland [13],
discount rates of 5% for costs and 3.5% for outcomes are
recommended. In the present guideline, the same discount rate
is used because the growth rate of the value of health is unclear.
Uncertainty
There are numerous uncertainties associated with the results of
economic evaluation. Thus, it is important to quantify and
present the degree of uncertainty in a clear manner.
Heterogeneity is a part of uncertainty in the broad sense. It
means that factors such as comparators, patterns of clinical
practice, and patient populations vary. If these factors vary to
an extent that inﬂuences results, sensitivity analysis should be
performed on the basis of various scenarios.
We classiﬁed uncertainty narrowly as 1) model uncertainty
and 2) parameter uncertainty. Model uncertainty results from
methodological uncertainty and the structure and assumption of
models. Methodological uncertainty arises from issues such as
discount rates and methods to estimate QOL scores that cannot
be theoretically decided in one way. Uncertainty due to the
structure and assumption of models arises from factors such as
modeling of health states and treatment process, selection of
parameters, and assumptions that extrapolate observed data for
prognosis predictions. These types of uncertainties should be
evaluated in a sensitivity analysis of parameters. In addition, if
analyses have a high degree of uncertainty because of a long time
horizon, analyses with a shorter time horizon should also be
performed.
Parameter uncertainty results from uncertainty in parameter
estimations. To deal with uncertainty caused by statistical
inference, probabilistic and deterministic sensitivity analyses
should be performed [48,49]. In the present guideline, probabil-
istic sensitivity analysis is also recommended, when possible.
Reporting/Publication
The model and other parameters for the CEA should be sub-
mitted in the form of an electronic ﬁle by manufacturers. The ﬁle
must be understandable to third-party experts and the parame-
ters must be editable. The analysis/review results should also be
made public. If, however, some incorporated data are difﬁcult to
publish because of intellectual property considerations, these
data may be speciﬁed in advance.Discussion
This is the ﬁrst ofﬁcially established guideline for economic
evaluation in Japan. The guideline was drafted on the basis of
discussions with the Chuikyo subcommittee. Most of the sub-
committee members were not experts in economic evaluation,
and some members had competing interests with each other.
This is the main reason for the delay in obtaining a consensus. By
the end of the discussions, many members readily understood
the concept of economic evaluation, even from a technical
perspective. Although the consensus reached on methodological
issues appeared reasonable to us, further discussions may con-
tribute to consensus building among various stakeholders.
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implementation is unclear, because this depends on future
discussions within the Chuikyo. Our guideline is intended for
the trial implementation phase. If the policy of economic evalua-
tion largely changes by the time of full implementation, the
guideline may need to be revisited and revised.
We established a methodological guideline for cost-
effectiveness evaluation, although some issues need to be
addressed for full implementation. For example, in Japan, there
is a shortage of experts in economic evaluation. Experience of
performing such evaluations is also limited in industries,
because economic data have not been requested from authorities
for a long period. Capacity building for cost-effectiveness evalua-
tion is important for full implementation. Moreover, Japanese
data on costs and QOL for economic analysis are at present
insufﬁcient. Thus, we as health economists must promote the
collection of data, in particular those pertaining to QOL and
costs.
This guideline requires that results of economic evaluation be
reported in a particular style, which we modeled after the
Consolidated Health Economic Evaluation Reporting Standards
(CHEERS) statement developed by the ISPOR task force [50] and
the style used by other HTA agencies. A common style is
important for standardizing and improving the quality of reports,
and the present style requires the following eight items: 1)
characteristics of drugs or medical devices, 2) setting of CEA, 3)
additional beneﬁt in effectiveness/safety, 4) detailed analysis
method, 5) results of analysis, 6) data for review, 7) members
involved in the analysis, and 8) references. Some subitems also
exist under the eight items. This style was reviewed by the
manufacturers of drugs and medical devices.
We did not include the controversial issue of equity consid-
erations for QALY. The controversy relates to whether all QALYs
should be equally treated or should be weighted on the basis of
the situation [51–53]. For example, NICE considers QALYs gained
at the end of life, although they insist “in the reference case, an
additional QALY should receive the same weight regardless of
any other characteristics of the people receiving the health
beneﬁt” [20]. We believe that equity considerations are important,
and the Chuikyo subcommittee expressed an interest in ethical
considerations in cost-effectiveness evaluation. Ethical and social
issues should be discussed in the future in the presence of an
expert organization on cost-effectiveness evaluation, which was
newly established for the “appraisal” phase. Unlike the NICE
guideline [20], the present guideline focuses only on the
“assessment” phase.
In the trial implementation phase, the cost per QALY thresh-
old is not determined. Some Chuikyo subcommittee members
supported the role of a threshold and the MHLW also suggested
the introduction of a threshold. This was, however, opposed by
some members. Therefore, unlike the NICE guideline, the present
guideline does not provide a cost per QALY threshold value. Our
research team suggested to the Chuikyo three methods to
calculate the threshold: 1) comparison with the efﬁciency of
technologies already being reimbursed (i.e., opportunity costs),
2) willingness to pay, and 3) gross domestic product per capita.
Referring to values determined by these, discussions on thresh-
old will continue among members of the subcommittee during
the trial implementation phase.
We believe that our newly developed guideline will contribute
to the improved quality and comparability of submitted cost-
effectiveness data by manufacturers. It may also facilitate dis-
cussions at the Chuikyo and contribute to the deﬁnitive intro-
duction and expansion of target technologies.
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